NTHI Neonc Technologies Holdings, Inc.
HealthcareAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-9.40
P/S
0.00
EV/EBITDA
-3.09
DCF Value
$-0.71
FCF Yield
-20.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
284.3%
ROA
-1160.3%
ROIC
259.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $0.00 | $-8.8M | $— |
| Q4 null | $0.00 | $-15.5M | $— |
| FY null | $40.0K | $-62.1M | $— |
| Q3 null | $0.00 | $-8.6M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$16.00
Target (Median)
$15.00
Target Range
$13.00 - $20.00
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.19
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.